Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
ProShares Ultra Energy
DIG
5
VanEck Oil Services ETF
OIH
US Stock MarketDetailed Quotes
Spyre Therapeutics (SYRE)
- 81.670
- +0.900+1.11%
Trading Jun 12 13:46 ET
7.09BMarket Cap-38.52P/E (TTM)
84.430High80.770Low336.56KVolume81.090Open80.770Prev Close27.83MTurnover0.42%Turnover RatioLossP/E (Static)86.84MShares84.43052wk High13.77P/B6.61BFloat Cap13.93052wk Low--Dividend TTM80.94MShs Float318.750Historical High--Div Yield TTM4.53%Range %2.650Historical Low82.684Avg Price1Lot Size
Spyre Therapeutics (SYRE) News
S&P 500 Futures Climb In Premarket Trading; Navan, AXT Lead
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics Shares Are Trading Higher After Deutsche Bank Maintained Its Buy Rating on the Stock and Raised Its Price Target From $102 to $115.
CrowdStrike To Surge Nearly 25%? Here Are 10 Notable Analyst Calls From Thursday
Deutsche Bank Maintains Buy on Spyre Therapeutics, Raises Price Target to $115
Navitas Semiconductor, Abivax, MiniMed And Other Big Stocks Moving Higher On Wednesday
Evercore Maintains Spyre Therapeutics(SYRE.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (ARDT), Vera Therapeutics (VERA) and Spyre Therapeutics (SYRE)
Express News | Spyre Therapeutics - Reiterates Expected Q3 2026 Readout for Rheumatoid Arthritis (Ra) and Q4 2026 Readouts for Psa and Axspa
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (Anti-TL1A) in RA, PsA, and AxSpA
Express News | Spyre Therapeutics Announces Completion of Enrollment in Skyway Basket Trial Evaluating Spy072 (Anti-Tl1a) in Ra, Psa, and Axspa
Spyre Expands SPY003 Rights Beyond Inflammatory Bowel Disease
Express News | Spyre Therapeutics - Material Deal Triggers End of Dosing Restrictions Outside Initial Field After June 1, 2028 - SEC Filing
Express News | Spyre Therapeutics - Amendment Expands Field to All Uses With Dosing Restrictions Outside Ibd Until 2028/2030 - SEC Filing
Express News | Spyre Therapeutics - Enters First Amendment to License Agreement With Paragon Therapeutics on May 29, 2026 - SEC Filing
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $95
Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (CGON) and Spyre Therapeutics (SYRE)
LifeSci Capital Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)
Healthcare Stocks With A+ Momentum Investors Are Watching
Market Insights
China Concept Stocks China Concept Stocks
Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation. Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation.
View More
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
The U.S.-Iran negotiations have entered a critical window! According to Bloomberg, both sides are close to signing a memorandum of understan
牛牛課堂
Mar 4 17:09
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
牛牛課堂
Mar 18 18:18
Hormuz, Term Structure and USO: Navigating the Energy Storm